PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPY | Publicación